Provided by Tiger Trade Technology Pte. Ltd.

Metagenomi Technologies, LLC

1.17
-0.0100-0.85%
Post-market: 1.170.00000.00%19:30 EDT
Volume:239.77K
Turnover:280.33K
Market Cap:44.20M
PE:-0.47
High:1.19
Open:1.19
Low:1.13
Close:1.18
52wk High:3.95
52wk Low:1.13
Shares:37.78M
Float Shares:25.57M
Volume Ratio:2.71
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4900
EPS(LYR):-2.3634
ROE:-60.61%
ROA:-28.19%
PB:0.39
PE(LYR):-0.50

Loading ...

Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference

GlobeNewswire
·
Yesterday

MGX JV Awards $38m Groundrush Decline Contract to Macmahon

TIPRANKS
·
Aug 31

Central Tanami JV advances Groundrush decline and resource drilling

TIPRANKS
·
Aug 31

Discovering ASX Penny Stocks: Centaurus Metals Among 3 To Watch

Simply Wall St.
·
Aug 24

MGX Resources (ASX:MGX) Shares Confront Koolan Write Downs And Cash Rich Pivot

Simply Wall St.
·
Aug 23

MGX pivots from iron ore to gold as Koolan Island wind-down funds Central Tanami push

TIPRANKS
·
Aug 21

MGX Resources Posts Deeper Loss as Revenue Slumps but Expands Tanami Stake

TIPRANKS
·
Aug 21

J.P. Morgan Keeps Their Hold Rating on Metagenomi, Inc. (MGX)

TIPRANKS
·
Aug 18

ProMIS Neurosciences Q2 Net Loss Widens

Reuters
·
Aug 14

Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Simply Wall St.
·
Aug 13

Upstream Bio Q2 Net Loss Narrows Slightly on Lower R&D Costs

Reuters
·
Aug 11

Metagenomi price target lowered to $7 from $9 at Wells Fargo

TIPRANKS
·
Aug 11

Metagenomi, Inc. (MGX) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 11

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Metagenomi Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 11

DiaMedica Q2 Net Loss Widen Less than Expected

Reuters
·
Aug 11

Perspective Therapeutics Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 11

Biotech Firm Nkarta Posts Q2 Net Loss; Cash Runway into 2029

Reuters
·
Aug 11

Metagenomi Q2 EPS $(0.73) Misses $(0.57) Estimate, Sales $(257.000K) Miss $2.960M Estimate

Benzinga Earnings
·
Aug 11

Metagenomi Targets 2027 Clinical Trial Start for Hemophilia a Genome-Editing Candidate MGX-001

Reuters
·
Aug 11